Olanzapine + Ziprasidone
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperglycemia
Conditions
Hyperglycemia, Hyperlipidemia
Trial Timeline
Feb 1, 2009 → Jun 1, 2012
NCT ID
NCT00910988About Olanzapine + Ziprasidone
Olanzapine + Ziprasidone is a pre-clinical stage product being developed by Pfizer for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00910988. Target conditions include Hyperglycemia, Hyperlipidemia.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00910988 | Pre-clinical | Completed |
| NCT00145444 | Phase 3 | Completed |
Competing Products
9 competing products in Hyperglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Human regular insulin + Insulin lispro + Insulin glargine | Eli Lilly | Phase 3 | 77 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200 | Merck | Phase 1 | 33 |
| liraglutide + placebo | Novo Nordisk | Pre-clinical | 22 |
| NPH insulin plus Complete Insulin Orders + Complete Insulin Orders | Sanofi | Approved | 84 |
| insulin glargine + insulin glargine + insulin glargine | Sanofi | Approved | 84 |
| Lantus® (insulin glargine) | Sanofi | Phase 1 | 32 |
| insulin glargine recombinant + therapeutic insulin | Sanofi | Phase 3 | 76 |